Active
MRD as a prognostic and surrogate marker in AML (HARMONY)
Cancer Genomics and Classification of Leukemia
Supported by the José Carreras Leukemia Foundation (DJCLS), this program uses hierarchical Dirichlet mixture models and other data-driven methods to investigate measurable residual disease in AML. It is a collaboration with HARMONY / IBSAL in Salamanca and FIDIS in Santiago de Compostela.
What problem are we trying to solve?
How can data-driven methods, including hierarchical Dirichlet mixture models, be used to investigate measurable residual disease in AML?
Why it matters
Measurable residual disease may refine risk after treatment and, if validated as a surrogate, could shorten trials.
Approach
HARMONY Alliance analyses discussed by Turki at ASH 2025. In the VJHemOnc interview he attributes a large MRD-surrogacy analysis to a colleague. Public copy must not over-claim authorship.